Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase 2
Completed
- Conditions
- Hematologic MalignanciesAcute Myeloid LeukemiaLymphoid LeukemiaChronic Myeloid LeukemiaHodgkin's DiseaseNon-Hodgkin's LymphomaMyelodysplastic Syndromes
- Interventions
- Drug: StemEx®
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Gamida Cell -Teva Joint Venture Ltd.
- Target Recruit Count
- 101
- Registration Number
- NCT00469729
- Locations
- 🇺🇸
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, Maywood, Illinois, United States
🇺🇸UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇮🇱Hebrew University Hospital Ein-Karem, Department of Bone Marrow Transplantation And Cancer Immunotherapy, Jerusalem, Israel
© Copyright 2025. All Rights Reserved by MedPath